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Influence of Obstructive Sleep Apnea
on Mortality in Patients With Heart Failure
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John S. Floras, MD, DPHIL, FACC,†‡ Susanna Mak, MD, PHD,† Kuo-Liang Chiu, MD, MSC,*
Pimon Ruttanaumpawan, MD,* George Tomlinson, PHD,‡ T. Douglas Bradley, MD*‡§
Toronto, Ontario, Canada
Objectives This study sought to determine, in patients with heart failure (HF), whether untreated moderate to severe ob-
structive sleep apnea (OSA) is associated with a higher mortality rate than in patients with mild to no sleep
apnea (M-NSA).
Background Obstructive sleep apnea is common in patients with HF and exposes the heart and circulation to adverse me-
chanical and autonomic effects. However, its effect on mortality rates of patients with HF has not been reported.
Methods In a prospective study involving 164 HF patients with left ventricular ejection fractions (LVEFs) 45%, we per-
formed polysomnography and compared death rates between those with M-NSA (apnea-hypopnea index [AHI]
15/h of sleep) and those with untreated OSA (AHI 15/h of sleep).
Results During a mean ( SD) of 2.9  2.2 and a maximum of 7.3 years of follow-up, the death rate was significantly
greater in the 37 untreated OSA patients than in the 113 M-NSA patients after controlling for confounding fac-
tors (8.7 vs. 4.2 deaths per 100 patient-years, p  0.029). Although there were no deaths among the 14 pa-
tients whose OSA was treated by continuous positive airway pressure (CPAP), the mortality rate was not signifi-
cantly different from the untreated OSA patients (p  0.070).
Conclusions In patients with HF, untreated OSA is associated with an increased risk of death independently of confounding
factors. (J Am Coll Cardiol 2007;49:1625–31) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.046o
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Central and obstructive sleep apnea (OSA) are
common in patients with heart failure (HF), in
whom they may worsen prognosis by increasing
sympathetic nervous system activity (SNA), rais-
ing blood pressure and triggering myocardial
ischemia and arrhythmias (1–6). Several studies
ave reported on mortality associated with central sleep apnea
n patients with HF (7–11). However, only 1 study examined
he potential influence of OSA on mortality in HF patients
11). Although that study reported no influence of OSA on the
ombined rate of death and heart transplantation, it was
nconclusive for several reasons. First, most patients were on a
eart transplant list at the time of enrollment, so that the
iming of transplantation was a matter of chance based on
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Department of Medicine of the Mount Sinai Hospital, ‡Department of
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erck-Frosst; Dr. Parker by a Career Investigator Award from the Heart and
troke Foundation of Ontario; Dr. Floras by a Canada Research Chair in 2rgan availability. Second, in the survival analysis of HF
atients with OSA, no distinction was made between patients
hose OSA was treated versus those in whom it was not
reated by continuous positive airway pressure (CPAP). Thus,
either the potential influence of untreated OSA nor of
reating OSA on survival was examined.
See page 1632
Obstructive apneas expose the cardiovascular system to
ntermittent hypoxia and sympathetic activation (12), and in
ddition, generate exaggerated negative intrathoracic pres-
ure, which increases left ventricular wall tension and lowers
troke volume (13,14). Such stresses could contribute to
ntegrative Cardiovascular Biology and a Career Investigator Award from the
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Furthermore, cross-sectional
data from the Sleep Heart
Health Study showed that the
presence of OSA was associated
with increased odds of having
HF, independently of known risk
factors (15). Epidemiologic stud-
ies involving patients with HF
have reported prevalences of
OSA of 12% to 53% (4,5,16).
These data suggest that OSA is
common in patients with HF,
and emphasize the importance
of determining its prognostic
significance.
If OSA contributes to mortal-
ity in HF, then its treatment
might improve prognosis. Ran-
domized trials show that allevia-
tion of OSA by CPAP in pa-
tients with HF lowers SNA,
blood pressure, and heart rate;
ncreases left ventricular ejection fraction (LVEF); and
educes nocturnal ventricular ectopy (17–20). However,
hus far, no study has examined the effect of CPAP on
ortality in HF patients with OSA. In a recent nonran-
omized observational study in patients without HF, Marin
t al. (21) reported that men with severe untreated OSA had
igher fatal and nonfatal cardiovascular event rates than
en without OSA. Conversely, fatal and nonfatal cardio-
ascular event rates in patients whose severe OSA was
reated by CPAP did not differ from subjects without OSA.
sing an observational design similar to that of Marin et al.
21), our primary objective was to determine, in patients
ith HF, whether untreated moderate to severe OSA is
ssociated with a higher mortality rate than in patients with
ild to no sleep apnea (M-NSA). A secondary objective
as to assess whether the mortality rate is lower in patients
hose OSA is treated by CPAP.
ethods
tudy design. In this prospective, observational epidemio-
ogic study, all patients with HF newly referred to the Heart
ailure Clinic of the Mount Sinai Hospital in Toronto
etween September 1, 1997, and December 1, 2004, un-
erwent overnight polysomnography. They were followed
p until January 1, 2005, at which point their vital status was
etermined. The protocol was approved by the local ethics
eview board, and all subjects provided written informed
onsent before entry.
ubjects. Candidates for inclusion were patients with: 1)
hronic HF caused by ischemic or nonischemic dilated
ardiomyopathy for at least 6 months; 2) left ventricular
Abbreviations
and Acronyms
AHI  apnea-hypopnea
index
BMI  body mass index
CPAP  continuous
positive airway pressure
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
M-NSA  mild to no sleep
apnea
NYHA  New York Heart
Association
OSA  obstructive sleep
apnea
SaO2  arterial oxygen
saturation
SNA  sympathetic
nervous system activityystolic dysfunction defined as a LVEF of 45% at rest by tadionuclide angiography or echocardiography performed
ithin 3 months before the diagnostic sleep study; 3)
yspnea (New York Heart Association [NYHA] functional
lass 2 to 4); and 4) stable clinical status on stable optimal
edical therapy for at least 1 month before entry. Exclusion
riteria were: 1) unstable angina, myocardial infarction, or
ardiac surgery within the previous 3 months; 2) pregnancy;
nd 3) prior history of sleep apnea.
olysomnography. Polysomnography was performed in all
ubjects using standard polysomnographic techniques (17).
leep stages and arousals were scored according to standard
riteria (22,23). Respiratory efforts and tidal volume were
easured by respiratory inductance plethysmography
Respitrace, Ambulatory Monitoring, Inc., White Plains,
ew York) (24). Arterial oxygen saturation (SaO2) was
onitored by oximetry. Obstructive apneas and hypopneas
ere scored according to established criteria (4,17). Patients
ere divided into categories according to the frequency of
pneas and hypopneas per hour of sleep (i.e., apnea-
ypopnea index [AHI]): M-NSA, AHI 15/h of sleep;
oderate to severe OSA (AHI 15/h of sleep, of which
50% were obstructive); and central sleep apnea (AHI
15/h of sleep, of which50% were central). Patients with
redominantly central sleep apnea were excluded from
urther analysis. The AHI cutoff of 15/h was chosen to
onform to that used in previous studies in which mortality
isk was associated with OSA in patients without HF (25),
nd the effects of CPAP on mortality in HF patients with
entral sleep apnea were tested (9,26).
Patients found to have OSA, and their cardiologists, were
nformed of their diagnosis. Subsequently, patients referred
o the sleep clinic for management of their OSA were
ffered CPAP. Patients who accepted CPAP therapy had a
econd overnight polysomnogram during which CPAP was
itrated to abolish OSA, or to the highest tolerated pressure.
er our usual clinical practice, these patients were evaluated
n our sleep disorders clinic 3 months later, and yearly
hereafter. Treated OSA was defined as initiation of CPAP
herapy, followed by documentation in the sleep disorders
linic that the patient continued to use CPAP at that time.
ll patients who were using CPAP at that time also
eported using it at their yearly clinic visits. Patients were
onsidered to have untreated OSA if they did not start
PAP, or if they started CPAP but stopped using it before
he 3-month follow-up clinic assessment (21).
utcome. The outcome was the cumulative rate of death
rom the date of the diagnostic sleep study until January 1,
005. For purposes of outcome analysis, patients with OSA
ere stratified into treated and untreated OSA groups. The
tatus of all subjects at this time was first ascertained by a
elephone call to them, their families, or their referring
hysicians. Dates and causes of death were obtained from
he subjects’ medical records, or where such records were
navailable, from their families or referring physicians.
tatistical analysis. Baseline characteristics of patients inhe 3 groups were compared by analysis of variance. Post
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April 17, 2007:1625–31 Sleep Apnea and Mortality in Heart Failureoc contrasts to assess differences between the untreated
SA and M-NSA groups and between the treated and
ntreated OSA groups were by 2-sided t tests for continu-
us variables, and by chi-square for nominal variables,
xcept where expected counts were 5, in which case, a
isher exact test was used.
To determine whether OSA increased the risk of death
ndependently of other risk factors, survival was compared
etween patients with M-NSA and those with untreated
SA in a multivariable Cox proportional hazards model
ver the course of the study. Because a 3-month follow-up
linic visit was not required to classify subjects as having
-NSA, or for those with OSA not prescribed CPAP as
eing untreated, this survival analysis started from the
aseline assessment. Confounding variables were those that
onferred at least a 10% change in the hazard ratio (HR) for
SA when added to the model (27). Independent variables
ere introduced into the model one at a time and included
VEF, NYHA functional class, age, gender, body mass
ndex (BMI), medications, and a history of hypertension,
iabetes, atrial fibrillation, and ischemic and nonischemic
ardiomyopathy.
For the comparison of survival between patients with
reated and untreated OSA, Kaplan-Meier survival analysis
nd the Prentice-Wilcoxon modification of the log-rank
est (28) were carried out. Because a 3-month clinic visit was
equired to determine whether an OSA patient was treated,
ubjects who died before the scheduled 3-month clinic visit
ere excluded from this survival analysis. A p value
f 0.05 was considered statistically significant. Data are
iven as mean  SD unless stated otherwise. All analyses
Figure 1 Progress of the Cohort Through the Study
AHI  apnea-hypopnea index; CSA  central sleep apnea; HF  heart failure; M-N
polysomnography.ere done using SPSS 12.0.1 (SPSS Inc., Chicago, Illinois). sesults
ubjects. We enrolled 218 patients with HF, of whom 45
21%) were found to have predominantly central sleep
pnea, and were excluded from further analysis; M-NSA
as found in 117 (54%) patients and OSA in 56 (26%).
atients were followed up prospectively for a mean of 2.9 
.2 years (range 1 month to 7.3 years), during which 9 (6%)
ere lost to follow-up. Complete follow-up data were
btained in 164 (95%) patients, of whom 113 had M-NSA,
7 had untreated OSA, and 14 had treated OSA (Fig. 1).
f the 37 patients with untreated OSA, 28 never started
PAP (mainly because of lack of hypersomnolence) (16),
nd 9 underwent a CPAP titration but discontinued it
efore their first follow-up clinic visit 3 months later.
ntreated OSA. PATIENT CHARACTERISTICS. Baseline
haracteristics of the patients with M-NSA and those with
ntreated OSA are shown in Table 1. For all comparisons of
ominal variables between the untreated OSA group and
he M-NSA group, chi-square tests were used. As expected,
he proportion of men was significantly higher in the
atients with untreated OSA than in those with M-NSA.
owever, neither age, BMI, LVEF, NYHA functional
lass, nor the proportion with a history of ischemic heart
isease, hypertension, or diabetes differed between the 2
roups. Epworth Sleepiness Scale scores were within normal
imits and were similar in the 2 groups as well (16,17).
edications and cardioverter-defibrillator use were also
imilar except that a higher proportion of untreated OSA
atients was on diuretics.
The mean AHI of patients with untreated OSA was 33/h of
mild to no sleep apnea; OSA  obstructive sleep apnea; PSG SA leep, indicating moderate to severe OSA (Table 2). They had
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Sleep Apnea and Mortality in Heart Failure April 17, 2007:1625–31ore frequent arousals from sleep, as well as significantly lower
inimum nocturnal SaO2 than the M-NSA group. However,
he mean SaO2 did not differ between the 2 groups.
ORTALITY. In the untreated OSA group, 9 (24%) died (5
udden death, 1 myocardial infarction, 3 progressive HF),
epresenting a mortality rate of 8.7 per 100 person-years,
hereas in the M-NSA group, 14 (12%) died (5 sudden
eath, 3 myocardial infarction, 6 progressive HF), indicat-
ng a mortality rate of 4.2 per 100 person-years (Fig. 2).
hree deaths in the untreated OSA group occurred in those
ho underwent a CPAP titration study, but who either did
ot receive CPAP at home, or quit using it before 3 months.
hese occurred 625, 724, and 814 days after enrollment.
nly 3 deaths occurred within 3 months of enrollment: 1
ccurred after 32 days in an M-NSA patient, and 2 occurred
fter 47 and 90 days in untreated OSA patients who never
Baseline Characteristics of the Patients
Table 1 Baseline Characteristics of the Pat
M-N
n 11
Age, yrs 53.5 
Gender, male/female 74
Body mass index, kg/m2 29.0 
Left ventricular ejection fraction, % 25.5 
NYHA functional class 2.4 
Ischemic cardiomyopathy, % 3
Nonischemic cardiomyopathy, % 6
History of hypertension, % 3
History of diabetes, % 2
History of hyperlipidemia, % 3
Epworth Sleepiness Scale 7.3 
Medications
Diuretics, % 7
Beta-blockers, % 8
ACE inhibitors, % 4
ACE inhibitors or AT2 antagonists, % 9
Digoxin, % 4
Statins, % 2
ICD, %
Continuous data are expressed as mean  SD. *p  0.05 compared
ACE  angiotensin-converting enzyme; AT2  angiotensin-2 recep
apnea; NYHA  New York Heart Association; OSA  moderate to sev
aseline Polysomnographic Data
Table 2 Baseline Polysomnographic Data
M-NSA Untreated OSA Treated OSA
Total sleep time, min 307.1 77.6 291.7 93.0 319.7 64.0
Sleep latency, min 22.4 22.5 22.4 30.4 17.8 24.6
Sleep efficiency, % 73.7 16.4 69.9 19.8 75.0 10.4
Apnea-hypopnea index,
n/h sleep
6.9 3.9 32.8 14.3* 38.8 15.9†
Obstructive events, % N/A 84.2 14.0 86.2 14.1
Movement arousals,
n/h sleep
17.8 13.7 31.7 11.7* 36.3 14.2†
Mean SaO2, % 95.1 2.1 94.6 2.8 93.9 3.9
Minimum SaO2, % 87.4 7.5 84.2 9.7 80.4 12.4†p  0.05 compared with M-NSA. †p  0.05 compared with untreated OSA.
SaO2  oxyhemoglobin saturation; other abbreviations as in Table 1.eceived CPAP. Thus, because we were able to ascertain
-NSA versus untreated OSA status at 3 months in all
ubjects, we were able to analyze mortality data from the
ime of enrollment.
The unadjusted HR showed a trend for increased mor-
ality in the untreated OSA versus the M-NSA groups that
Untreated OSA Treated OSA
37 14
58.5  12.0 53.2  9.4
32:5* 14:0*
30.1  5.2 32.3  4.5*
25.9  8.7 23.9  8.8
2.3  0.5 2.3  0.6
40.5 35.7
59.5 64.3
43.2 64.3
29.7 35.7
35.1 64.3*
7.6  3.8 7.4  2.9
91.9 71.4
83.8 78.6
54.8 53.8
89.2 100
48.6 35.7
30 38.5
0 7.1
NSA.
 implantable cardioverter-defibrillator; M-NSA  mild to no sleep
tructive sleep apnea.
Figure 2 Multivariable Cox Proportional Hazards Survival
Plots for Patients With M-NSA Versus Untreated OSA
Multivariable Cox proportional hazards plots showing worse survival of heart
failure patients with untreated obstructive sleep apnea (OSA) than in those
with mild to no sleep apnea (M-NSA) (hazard ratio  2.81, p  0.029) after
adjusting for significant confounders (left ventricular ejection fraction, New York
Heart Association functional class, and age per Table 3). The adjusted survival
curves are shown at the average values of these confounders.ients
SA
3
13.8
:39
5.4
10.3
0.7
5.4
4.6
4.5
2.1
1
3.9
2.6
1.4
6.9
3.8
2.5
9.3
4.4
with M-
w
H
(
r
w
0
t
s
i
T
t
v
c
c
l
f
u
e
g
O
w
g
a
h
w
v
a
(
M
p
c
a
a
l
g
b
f
3
p
(
a
m
s
D
O
m
i
s
m
w
t
o
1
s
o
y
a
L
d
0
a
c
o
A
(
c
p
t
i
v
v
o
c
r
r
w
b
d
d
a
(
w
t
L
m
t
(
e
i
t
o
m
a
C
g
M
L
1629JACC Vol. 49, No. 15, 2007 Wang et al.
April 17, 2007:1625–31 Sleep Apnea and Mortality in Heart Failureas of borderline significance (HR  2.024, p  0.099).
owever, after adjusting for the significant confounders
LVEF, NYHA functional class, and age) in the multiva-
iable Cox proportional hazards model, the HR associated
ith untreated OSA was significant (HR  2.81, p 
.029) (Table 3). The addition of other variables listed in
he statistical analysis section above did not lead to any
ubstantive changes to the HR, and are therefore not
ncluded in the final model.
reated OSA. PATIENT CHARACTERISTICS. Fourteen pa-
ients had treated OSA. For comparisons of nominal
ariables between the untreated and treated OSA groups,
hi-square tests were used for ischemic and nonischemic
ardiomyopathy, history of hypertension, history of hyper-
ipidemia, and digoxin, whereas Fisher exact tests were used
or comparisons of gender distribution, history of diabetes,
se of diuretics, beta-blockers, and angiotensin-converting
nzyme inhibitors.
There were no significant differences in baseline demo-
raphic characteristics between the untreated and treated
SA groups (Table 1). Epworth Sleepiness Scale scores
ere within normal limits and were similar in these 2
roups. Medication and cardioverter-defibrillator use was
lso similar. Patients with treated OSA had significantly
igher AHIs than patients with untreated OSA, but there
ere no significant differences in other polysomnographic
ariables, including frequency of arousals and the mean
nd minimum nocturnal SaO2 between the 2 groups
Table 2).
ORTALITY. There were no deaths in the 14 treated OSA
atients, and therefore the Cox proportional hazards model
ould not be used to adjust for other variables or to estimate
nd test significance of the HR. Instead, the Kaplan-Meier
nalysis and the Prentice-Wilcoxon modification of the
og-rank test were used. Two patients in the untreated OSA
roup who were never prescribed CPAP but who died
efore 3 months after the baseline assessment were excluded
rom this analysis. There were no patients who died within
months of starting CPAP. Among the 35 remaining
atients in the untreated OSA group, 7 died after 3 months
mortality rate of 7.2 per 100 person-years) versus 0 deaths
mong the 14 treated OSA patients. This trend for reduced
ortality in the treated OSA group, however, was not
ultivariate Hazards Ratios for Mortality Rate
Table 3 Multivariate Hazards Ratios for Mortality Rate
Variables Hazard Ratio p Value
95% Confidence
Interval
Lower Upper
Untreated OSA 2.81 0.029 1.11 7.10
LVEF 0.93 0.006 0.88 0.98
NYHA functional class 2.30 0.037 1.04 5.08
Age 1.05 0.005 1.02 1.09
VEF  left ventricular ejection fraction; other abbreviations as in Table 1.tatistically significant (p  0.07). viscussion
nly 1 previous study examined the influence of OSA on
ortality rate in patients with HF (11). However, that study
ncluded only 22 HF patients with OSA and 23 without
leep apnea. The results of that study were inconclusive
ainly because no distinction was made between patients
hose OSA was treated versus those in whom it was not
reated by CPAP. Therefore, the most important finding of
ur study was that in a much larger unselected population of
64 patients with HF, those with untreated OSA had a
ignificantly higher mortality rate than those with M-NSA
ver mean and maximum follow-up times of 2.9 and 7.3
ears, respectively. This difference remained significant even
fter controlling for those confounding variables (i.e., age,
VEF, and NYHA functional class) that altered indepen-
ently the HR relating OSA to mortality (HR  2.81, p 
.029) (27). Thus, in patients with HF, untreated OSA was
n independent risk factor for death.
We found that 26% of patients with HF recruited
onsecutively from an HF clinic, irrespective of symptoms
f sleep apnea, had moderate to severe OSA, defined as an
HI 15/h. Thus, OSA is common in patients with HF
4). There are many adverse effects of OSA that could
ontribute to the increased mortality rate we observed in HF
atients with untreated OSA. Generation of negative in-
rathoracic pressure during obstructive events causes both an
ncrease in left ventricular afterload and a decrease in left
entricular preload, accompanied by reductions in stroke
olume (14). Apnea-related hypoxia also can reduce cardiac
utput by impairing myocardial contractility (29) and in-
reasing pulmonary artery pressure (1). The combination of
epetitive apneas, hypoxia, and arousals from sleep stimulate
eflex increases in central SNA, which are greater in patients
ith than in those without HF (30). The resultant surges in
lood pressure further increase afterload and myocardial O2
emand. In the face of reduced O2 supply, this increase in O2
emand can provoke myocardial ischemia and arrhythmias,
nd may increase the risk of sudden death during sleep
6,31). Moreover, this increase in SNA is sustained into
akefulness (13). These effects summate with those of HF
o cause greater SNA than either condition alone (32).
ong-term exposure to elevated SNA can cause cardiac
yocyte necrosis and apoptosis, beta-adrenoceptor desensi-
ization, arrhythmias, and an increase in mortality rate
9,32,33). In addition, OSA is associated with vascular
ndothelial dysfunction (34), elevated C-reactive protein,
nflammatory mediators, cytokines, and markers of oxida-
ive stress (35–37), all of which could promote progression
f HF and reduce survival.
The second interesting finding of our study was that
ortality tended to be lower, although not significantly so,
mong the 14 HF patients whose OSA was treated with
PAP for at least 3 months than in the untreated OSA
roup over a mean follow-up period of 2.9 years (0 deaths
s. 7.2 deaths per 100 person-years, respectively, p 0.070).
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Sleep Apnea and Mortality in Heart Failure April 17, 2007:1625–31reated and untreated patients were comparable in terms of
ardiovascular conditions and risk factors including age,
ender distribution, BMI, LVEF, NYHA functional class,
nd diabetes. Medication use was similar in the 2 groups.
reated and untreated OSA patients were also comparable
or sleep-stage distribution, frequency of arousals, and mean
nd minimum SaO2, whereas treated OSA patients had a
igher AHI, indicating more severe OSA. Thus, if OSA is
risk factor for mortality in HF patients, those in the
PAP-treated group, who had more severe OSA than those
n the untreated OSA patients, should have had higher
ortality, rather than the trend to lower mortality that we
bserved. Therefore, our data suggest that in patients with
F, treatment of OSA by CPAP has the potential to
mprove survival. On the other hand, it could be that
atients with HF who accepted CPAP were more health
onscious or compliant with other treatments, and this
ight have had a beneficial effect on their survival.
These results follow logically from the results of previous
andomized clinical trials of CPAP in HF patients with
SA; CPAP reverses OSA acutely, eliminates apnea-
elated hypoxia, dampens negative intrathoracic pressure
wings, and lowers blood pressure (13). Randomized clinical
rials showed that treatment of OSA by CPAP in patients
ith HF reduces ventricular ectopy during sleep; lowers
lood pressure, heart rate and SNA during both sleep and
akefulness; and improves LVEF (17–20).
However, our observations regarding the effect of CPAP
n survival are subject to several limitations. First, although
here was a trend to lower mortality in the CPAP-treated
roup than in the untreated OSA group, this difference was
ot statistically significant. Second, CPAP was not allocated
andomly to patients. Third, we did not monitor hours of
PAP use, but rather simply recorded whether patients were
sing it or not at follow-up visits. Thus we could not be certain
f CPAP compliance or whether CPAP-treated patients
ontinued to use it throughout the study period. Finally,
ecause of the small number of subjects and deaths involved in
his analysis and the absence of any deaths in the treated OSA
roup, we were unable to control for potentially confounding
actors by use of multivariable Cox proportional hazards
nalysis. Many patients with OSA in our study were not
tarted on CPAP, most likely because they were not self-
eferred for sleep assessment and lacked subjective sleepiness,
hich is the usual indication for CPAP. Lack of sleepiness is
ompatible with their low Epworth Sleepiness Scale scores that
ere well within the nonsleepy range (mean 7.6) (Table 1), and
onsistent with previous reports (5,16,17,37,38). Among the 9
ho started CPAP but discontinued it before the 3-month
ollow-up clinic visit, most stopped because they were not
leepy beforehand, and as a consequence, either had no
eduction in daytime sleepiness or had difficulties tolerating the
PAP mask.
These observations are consistent with previous reports
ndicating that lack of daytime sleepiness and lower AHI are
ssociated with poor CPAP compliance (39). They also Ouggest that the lack of daytime sleepiness among HF
atients with OSA could pose an obstacle to good CPAP
ompliance in the clinical setting. We previously showed
xcellent CPAP compliance among nonsleepy HF patients
ith OSA in the setting of randomized trials (17,18,20).
owever, these trials involved more intensive follow-up,
hich in itself has been shown to improve CPAP compli-
nce, than the present clinic-based observational study (39).
imilar to the present findings, Roebuck et al. (11) reported,
n another observational study of CHF patients, that only
6% of patients with OSA were initiated on CPAP, and
nly one-half of those continued to use it for more than 6
onths. These observations suggest that maintenance of
ood CPAP compliance in HF patients with OSA who do
ot complain of hypersomnolence can be achieved, but that
t may require more intensive initiation and follow-up than
n the present study.
Our results are also compatible with those of Marin et al.
21), who performed a long-term nonrandomized observa-
ional study similar to ours, but only included men. That
tudy had several of the same limitations as ours. The
PAP was offered to patients with OSA in a nonrandom
ashion. Patients who did not accept it were considered
ntreated, whereas those who accepted CPAP and contin-
ed to use it were considered treated. Like us, they reported
hat patients with untreated OSA but without HF had a
igher cardiovascular mortality rate than those without
SA after controlling for confounding factors. Although no
irect comparison of mortality rate between treated and
ntreated OSA patients was made, the mortality rate in men
ith treated OSA did not differ from those without OSA.
Our findings also complement those of Marin et al. (21)
n several ways. First, in our study, patients both with and
ithout OSA did not come from a sleep clinic population,
ut were drawn from an unselected HF population. They
ere included regardless of the presence or absence of a
omplaint of excessive daytime sleepiness, and in fact, most
id not complain of sleepiness. In contrast, Marin et al. (21)
tudied patients referred to a sleep disorders clinic because
f a suspicion of sleep apnea, most of whom complained of
leepiness. Data from the present study suggest that even in
he absence of subjective sleepiness, untreated OSA has an
dverse impact on prognosis in patients with HF. Second,
ecause we studied a different patient population who had
F and included both men and women, our results suggest
hat untreated OSA has generally adverse effects on survival
n diverse populations. Third, we compared survival directly
n treated and untreated HF patients with OSA, and
bserved a nonsignificant trend to greater survival in those
ho were treated.
onclusions
ata from this prospective observational study with up to
.3 years of follow-up suggest that in patients with HF,
SA confers an increased risk of death independently of
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or treatment of OSA by CPAP in patients with HF to
mprove survival beyond that achieved with optimal phar-
acological therapy, our data cannot be considered defini-
ive in this latter respect because this tendency was not
tatistically significant, and because of the limitations of our
tudy design as previously discussed. These observations do,
owever, provide a strong rationale for conducting a large-
cale, randomized trial to determine whether treating OSA
n patients with HF improves survival.
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